Related Experiment Video
Updated: Mar 14, 2026
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Tumor-derived cystatin C enables amyloid clearance
Joseph Zambelas1, Yun Huang2, Hong Zhao3
1Department of Systems Medicine and Bioengineering, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX 77030, USA; Weill Cornell Medicine at Houston Methodist Neuroscience PhD Program, Houston, TX 77030, USA.
Alzheimer's disease amyloid plaques are cleared by tumor-derived cystatin C, which activates microglial phagocytosis. This neuroimmune mechanism reduces amyloid burden and improves cognition, offering a targeted therapy approach.
Area of Science:
- Neuroimmunology
- Alzheimer's Disease Pathophysiology
- Molecular Mechanisms of Neurodegeneration
Background:
- Amyloid pathology is a hallmark of Alzheimer's disease (AD), contributing to neurodegeneration and cognitive decline.
- Current therapeutic strategies for AD often involve broad immune modulation, which can have off-target effects.
- Understanding specific neuroimmune mechanisms involved in amyloid clearance is crucial for developing targeted therapies.
Purpose of the Study:
- To elucidate a novel tumor-derived neuroimmune mechanism that facilitates the clearance of established amyloid pathology in Alzheimer's disease.
- To investigate the role of secreted cystatin C in modulating microglial function and amyloid plaque burden.
- To explore a context-dependent therapeutic strategy for Alzheimer's disease targeting substrate-coupled amyloid clearance.
Main Methods:
- Utilized in vivo and in vitro models of Alzheimer's disease to study amyloid pathology.
- Investigated the interaction between secreted cystatin C and microglial receptors, specifically TREM2.
- Assessed the impact of cystatin C on microglial phagocytosis of amyloid-beta plaques.
- Evaluated cognitive function in mouse models following intervention.
Main Results:
- Demonstrated that tumor-derived secreted cystatin C activates TREM2-dependent microglial phagocytosis.
- Showed that cystatin C treatment leads to a significant reduction in amyloid plaque load in established Alzheimer's disease models.
- Observed improvements in cognitive performance in treated animals, correlating with reduced amyloid burden.
- Identified a neuroimmune pathway where cystatin C acts as a specific substrate-driven modulator.
Conclusions:
- Secreted cystatin C represents a key mediator in a tumor-derived neuroimmune mechanism for clearing Alzheimer's disease amyloid pathology.
- Targeting the TREM2-dependent microglial phagocytosis pathway activated by cystatin C offers a promising therapeutic avenue for Alzheimer's disease.
- This research shifts the paradigm for Alzheimer's therapy towards specific, substrate-coupled amyloid clearance rather than broad immune activation.
Related Concept Videos
03:03Amyloid Fibrils
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...